OptimizeRx (OPRX) Receives a Buy from RBC Capital
November 10 2022 - 08:49PM
TipRanks
In a report released on November 9, Sean Dodge from RBC Capital
maintained a Buy rating on OptimizeRx (OPRX - Research Report),
with a price target of $22.00. The company's shares closed
yesterday at $20.36.Dodge covers the Technology sector, focusing on
stocks such as Allscripts, OptimizeRx, and NextGen Healthcare.
According to TipRanks, Dodge has an average return of -6.2% and a
42.68% success rate on recommended stocks. OptimizeRx has an
analyst consensus of Strong Buy, with a price target consensus of
$27.00, a 32.61% upside from current levels. In a report released
on November 9, B.Riley Financial also maintained a Buy rating on
the stock with a $37.00 price target.
https://www.tipranks.com/news/blurbs/optimizerx-oprx-receives-a-buy-from-rbc-capital?utm_source=advfn.com&utm_medium=referral
OptimizeRx (NASDAQ:OPRX)
Historical Stock Chart
From Sep 2023 to Oct 2023
OptimizeRx (NASDAQ:OPRX)
Historical Stock Chart
From Oct 2022 to Oct 2023
